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Abstract
Background: Although the recommended cut-point for cardiac troponin (cTn) is the 99th
percentile, many institutions use cut-points that are multiples higher than the 99th percentile for
diagnosing acute myocardial infarction (AMI). Prior studies have shown that patients with a
HEART score (HS) ≤ 3 and normal serial cTn values (modified HS) are at low risk for adverse

D

events. This study aimed to evaluate the prognostic utility of the HS when various cTn cut-points
are used.

TE

Methods: This was a sub-study of TRAPID-AMI, a multicenter, international trial evaluating a
rapid rule-out AMI study using high sensitivity cTnT (hs-cTnT). 1,282 patients were evaluated
for AMI from 12 centers in Europe, United States of America, and Australia from 2011-2013.

EP

Blood samples of hs-cTnT were collected at presentation and 2 hours, and each patient had a HS
calculated. The US Food and Drug Administration approved 99th percentile for hs-cTnT (19
ng/L) was used.

Results: There were 213 (17%) AMIs. Within 30 days, there were an additional 2 AMIs and 8

C

deaths. The adverse event rates at 30 days (death/AMI) for a HS ≤ 3 and non-elevated hs-cTnT
over 2 hours using increasing hs-cTnT cut-points ranged from 0.6% to 5.1%.

C

Conclusions: Using the recommended 99th percentile cut-point for hs-cTnT, the combination of

a HS ≤ 3 with non-elevated hs-cTnT values over 2 hours identifies a low-risk cohort who can be

A

considered for discharge from the emergency department without further testing. The prognostic
utility of this strategy is greatly lessened as higher hs-cTnT cut-points are used.
Keywords: high sensitivity troponin, hs-cTnT, modified HEART score, HEART score
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Introduction
Cardiac disease is the leading cause of death in the United States,1 and annually there are more
than 780,000 acute myocardial infarctions (AMIs) diagnosed.2 There are approximately 8 to 10
million people that are evaluated each year for possible AMI in the United States.3 This
comprises 5% to 10% of emergency department (ED) visits, out of which the majority are not

D

diagnosed with AMI.4 Moreover, approximately 2% of AMI cases are missed and discharged

from the ED, which subsequently leads to adverse outcomes.5 There is a substantial amount of

TE

cost, time, and resources that are utilized in this evaluation including laboratory tests, stress tests,
and cardiac imaging.

Cardiac troponin (cTn) measurements are fundamental in the evaluation of AMI. Over time, cTn

EP

has emerged as the preferred cardiac marker in evaluation for AMI due to improved sensitivity
and risk stratification.6 Based on the Fourth Universal Definition of Myocardial Infarction
consensus document published in 2018, AMI diagnostic criteria include rising and falling
patterns of cTn with at least one value that exceeds the 99th percentile limit of a normal reference

C

population.7 Guidelines from multiple professional societies recommend using the 99th percentile
as the appropriate cTn cut-point for determination of AMI.7-9 In fact, use of the 99th percentile

C

has been associated with improved outcomes and increase in the frequency of diagnosis of
AMI.10,11 This recommendation was made in hopes of establishing a standard in the diagnosis of

A

AMI; however, it is not commonly utilized worldwide.
Many institutions use cTn cut-points that are much higher than the 99th percentile, which directly
affects patient management and resource utilization. In a study of 276 hospitals in 31 countries,
there was a large variability across laboratories in the cTn threshold that was used, with more
than 25% using cut-points > 5 times the 99th percentile and 15% using cut-points > 10 times the

5
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99th percentile.12 A study of 824 hospitals in the United States showed that only 49% used the
99th percentile.13 The CARdiac MArker Guidelines Uptake study demonstrated that only 52% of
European laboratories and 45% of United States laboratories utilized the 99th percentile limit for
diagnosis of AMI.14
Risk scores such as the Emergency Department Assessment of Chest Pain Score, HEART score

D

(HS) and Thrombolysis in Myocardial Infarction (TIMI) score are used to predict the probability
of future major adverse cardiac events (MACE) in patients presenting to the ED who are

TE

evaluated for possible AMI.15 The original HS was calculated in such a fashion where a patient
could have an elevated high sensitivity cardiac troponin (hs-cTn) greater than the 99th percentile
and still be considered low-risk. A modified-HS (m-HS) strategy has been described that

EP

identifies a very low-risk population with low hs-cTn measurements and a HS ≤ 3 who could be
considered for discharge from the ED without stress testing or cardiac imaging.16 We specifically
studied the HS in combination with hs-cTnT to identify patients at low risk for 30-day MACE.
The aim of this study was to describe the prognostic utility of the m-HS when various cut-points

Methods

C

of hs-cTnT are used.

C

Study Design and Population

The study consisted of a sub-study analysis of the TRAPID-AMI (High Sensitivity Cardiac

A

Troponin T assay for RAPID Rule-out of Acute Myocardial Infarction) study, which was a
multicenter, international diagnostic study in the ED evaluating a rapid rule-out AMI protocol
over 1 hour using changes in hs-cTnT (Roche Diagnostics, Penzberg, Germany). Details of the
study have previously been published.17 There were 1,282 patients evaluated in the ED for
possible AMI from 12 centers in Europe, the United States of America, and Australia studied

6
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from 2011 to 2013. Patients were interviewed by research personnel to determine demographics
and presenting symptoms at time of presentation to the ED. Patients were excluded if they had
renal failure requiring hemodialysis and all participants provided written informed consent. The
study was approved by the Henry Ford Hospital Institutional Review Board. The study protocol

approval by the institution's human research committee.

D

conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori

Blood samples for determination of hs-cTnT (Roche Diagnostics) and cardiac troponin I-ultra

TE

(cTnI-ultra) (Siemens Healthcare, Tarrytown, NY) were collected at presentation and 1, 2, and 414 hours. Thereafter, centrifugation samples were frozen at -80°C until assayed using the Elecsys
2010 (Roche Diagnostics) instrument. The limit of detection, 10% coefficient of variation, and

EP

99th percentile of a reference population have been reported at 5 ng/L, 13 ng/L, and 14 ng/L,
respectively.18 The 14 ng/L is the 99th percentile value used outside of the US. The cTnI-ultra
assay was performed using the Siemens ADVIA Centaur immunoassay system with a limit of
detection, 10% coefficient of variation, and 99th percentile of 6 ng/L, 30 ng/L, and 40 ng/L,

C

respectively.19,20

The diagnosis of AMI was centrally adjudicated by 2 independent cardiologists in accordance

C

with the universal definition of AMI, and adjudicated by a third cardiologist in case of
disagreement, using all available clinical information and serial measurements of cTnI-ultra.21

A

AMI was diagnosed when there was evidence of myocardial necrosis on the basis of a significant
rise or fall pattern of the cTnI concentration in a setting consistent with myocardial ischemia
(ischemic symptoms, electrocardiogram [ECG] changes, or imaging evidence). The 99th
percentile of this assay (40 ng/L) was used as a cutoff for myocardial necrosis. An absolute

7
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change of 20 ng/L or greater with the cTnI-ultra assay during the study was used to define a
significant rise and fall.22
Modified HS Criteria
Elements of the traditional HS have been described in prior studies.23,24 The calculation of the
HS includes elements of the history, ECG, age, and risk factors. Each of these categories are

D

assigned a 0 (low risk), 1 (moderate risk), or 2 (high risk) and then added into a composite score.
The history was categorized retrospectively as either high, moderate, or low suspicion for AMI

TE

by using a modified Diamond-Forrester prediction rule25 including the presence of chest
pressure, worsening with physical activity, and radiation to arms or shoulders. Relief of

symptoms with rest, used in the original Diamond-Forrester tool, was not used because this

EP

information was not collected. For the history component, patients were assigned 2 points if they
met 3, 1 point if they met 2, and 0 points if they met 1 or none of the criteria.
For ECG findings, 2 points were given if there was horizontal or down-sloping ST depression ≥
0.5 mm in 2 contiguous leads or ST elevation ≥ 1 mm in 2 contiguous leads (if V2-V3 was

C

involved, then the following applied: ≥ 2 mm in males ≥ 40 years, ≥ 2.5 mm in males < 40 years,
and ≥ 1.5 mm in females); 1 point was given for either right or left bundle branch block, left

C

ventricular hypertrophy, or ventricular paced rhythm; 0 point was given if the ECG did not meet
any of the criteria of the other 2 categories. ECGs were categorized by independent cardiologists

A

who were blinded to all clinical information.
Patients ≥ 65 years of age were assigned 2 points, those 45 to 64 years were given 1 point, and
patients < 45 years received 0 points. For risk factors, patients were assigned 2 points for ≥ 3
cardiac risk factors or a history of coronary artery disease (prior AMI, percutaneous coronary
intervention, or coronary artery bypass grafting surgery), 1 point for 1 to 2 cardiac risk factors,

8
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and 0 point for 0 risk factors. Cardiac risk factors included in this analysis were hypertension,
diabetes mellitus, and smoking history. Hyperlipidemia and family history were not included
because this information was not collected. Each patient had a HS calculated. The 30-day
death/AMI rate was reported using the m-HS at various cut-points multiples higher than the 99th
percentile. These calculations were done for the 99th percentile used outside of the US (14 ng/L)

D

and for the US Food and Drug Administration (FDA) approved 99th percentile (19 ng/L).26
Statistical Analysis

TE

The baseline demographic and comorbidity variables have been compared between the elevated
and non-elevated HS patients using a 2-sample t-test for numerical data and chi-square test for
categorical data. Within each troponin setting, the AMI/death status at 30 days has been

EP

compared between the elevated and non-elevated HS patients using the chi-square test when
there were no expected cell counts < 5, otherwise using Fisher’s exact test. Resulting p-values <
0.05 have been considered statistically significant for this descriptive study.
Results

C

There were 1,282 patients evaluated, of which there were 213/1282 (16.6%) AMIs, consisting of
21 ST-segment elevation myocardial infarctions, and 192 non-ST-segment elevation myocardial

C

infarctions, and 8 deaths. At 30 days, there were 2 additional AMIs diagnosed, yielding 217
(16.9%) patients with a 30-day MACE (6 patients had an AMI and subsequently died). Because

A

of missing HS data, 47 patients were excluded, leaving 1,235 patients to be evaluated with the
modified HS.

Baseline demographics are shown by HS status without consideration of hs-cTnT values (Table
1). Patients with higher HS were older and more commonly had cardiac risk factors. The adverse
event rates at 30 days (death/AMI) are shown for elevated HS ≥ 4, non-elevated HS ≤ 3, and

9
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non-elevated hs-cTnT over the various time intervals (hours) using various hs-cTnT cut-points
(Table 2 and Supplemental Digital Content Table 1 http://links.lww.com/HPC/A233 ), using
both 19 ng/L and 14ng/L as the upper reference limit. As higher hs-cTnT cut-points were used,
the 30-day MACE rate increased for those deemed to be low risk by the modified HS. The 30day death/AMI rate for different hs-cTnT cutoffs alone without taking modified HS in

D

consideration was also calculated (Table 3). These results highlighted the increasing risk with
higher hs-cTnT cut-points and were observed to be numerically higher compared to the

TE

combined use of the HS. The net reclassification improvement (NRI) comparing performance of
lowest cut point of hs-cTnT to different hs-cTnT cut points including 99th percentile (19 ng/L)
was generated with Table 3 used as reference (Supplemental Digital Content Table 2

each cut-point.
Discussion

EP

http://links.lww.com/HPC/A233 ). Specifically, we focused on time interval 0-(4-14) hours for

Early diagnosis of AMI is crucial for initiation of appropriate therapies. The evaluation for

C

possible AMI requires prompt clinical assessment along with objective data including cardiac
biomarker assays, especially cTn, which has emerged as the gold standard in the diagnosis of

C

AMI.27 The prognostic significance of a m-HS using various hs-cTnT cutoffs was analyzed. Our
findings demonstrate that 30-day MACE rate for the m-HS with serial hs-cTnT measurements

A

ranged from 0.7%-5.7% depending on the cut-point, with the lowest MACE rate using the
recommended 99th percentile cut-point. This is clinically relevant as many institutions use the HS
to help guide risk stratification and early discharge from the ED, especially for low risk patients.

10
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In fact, American Heart Association guidelines recommend utilization of clinical risk scores for
patients presenting with chest pain to aid with clinical decision making.28 There is an accepted
miss rate for 30-day MACE at 1% or less.29
Multiple studies have applied a serial testing troponin strategy with HS and demonstrated a
MACE rate of 0%-2%. A study by Baugh et al demonstrated 0% MACE using 99th percentile

D

troponin cut-point in patients undergoing standardized clinical assessment and management plan
for chest pain based on the HS.30 The TRAPID-AMI study utilized hs-cTnT and showed a 0.2%

TE

30-day MACE rate using a 0/1-hour protocol.16 Wang et al compared the performance of risk

scores such as HS, Global Registry of Acute Coronary Events, TIMI and showed < 1% MACE
rate using serial troponin-I (TnI) measurements at 4-6 hour intervals.31 The initial study

EP

validating the HS showed MACE rate of 0.4% in low HS (0-3) with cTnT (fourth generation) or
cTnI using 99th percentile cutoff limit.32 Similarly, a study looking at the HEART pathway
comprised HS with serial cTnI test at 0 and 3 hours and showed 0% MACE rate using 99th
percentile reference value.33 Mahler et al demonstrated MACE rate of 0.6% in patients with low

C

risk HS using TnI 99th percentile cutoff to support decreased utility of cardiac testing in those
with low probability of AMI.34 An analysis comparing HS and North American Chest Pain Rule

C

identified chest pain patients for early discharge and demonstrated < 1% MACE rate using 99th
percentile cTnI cut-point.35

A

Despite the Universal Definition of Myocardial Infarction recommendation for use of cTn

concentration at the 99th percentile of a normal reference population as the decision level for

diagnosis of AMI, there is substantial variation observed across institutions, which can impact
patient management.12 Consequently, there is an important need for standardization of cTn
threshold, which affects rapid rule out AMI protocols, testing strategies, costs, and length of

11
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hospitalization. Therefore, studies have looked at the prognostic utility of hs-cTn across different
cutoffs. A prospective, multicenter, observational study of patients with suspected AMI utilized
measurement of hs-cTnI to identify patients at low and high risk for AMI. Atellica IM TnIH and
ADVIA Centaur TNIH (Siemens Healthineers) assays were utilized, measuring cTn  limit of
detection at the 99th percentile upper reference limit.36 This study revealed threshold of < 5 ng/l

D

that identified a low risk cohort at presentation, with sensitivities of 98.6% and negative

predictive values of 99.6% for MACE at 30 days across both assays. The European Society of

TE

Cardiology Guidelines recommend the use of 0/1-hour algorithm for AMI evaluation which
utilizes values less than the 99th percentile with using of hs-cTn.37

Using the recommended 99th percentile cut-point for hs-cTnT, the combination of a HS with

EP

non-elevated hs-cTnT values identifies a low-risk cohort who can be considered for discharge
from the ED without further testing. The prognostic utility of this strategy is greatly lessened as
higher hs-cTnT cut-points are used. When comparing the MACE rates of patients with a HS ≤ 3
to those with a HS ≥ 4, the absolute difference between MACE rates was greater as higher hs-

C

cTnT cut-points were used. However, using these higher cut-points led to higher MACE rates

C

which suggests that the lower cut-points are desirable to identify a low-risk cohort who could be
directly discharged without further cardiac testing. Santi et al presented a low risk population
who could be discharged without any further cardiac risk stratification, revealing 512 (37.2%)

A

patients who met criteria for low HS in combination with hs-cTnT (99th percentile cutoff) with
no subsequent MACE (0%).24 Prevalence of MACE was noted to increase with higher HS, only
occurring in patients with a HS > 3. Studies have also shown that very low hs-cTn levels may
also obviate the need for risk scores. Neumann et al reported on over 22,000 patients who were

evaluated for possible AMI in the ED and found that patients with very low levels of hs-cTnI or
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hs-cTnT (well below the 99th%) at presentation, that were not changing significantly within 2
hours, were associated with a low likelihood of AMI and MACE (0.2%) at 30 days.38
Study Limitations
Our study does have some limitations to consider. HS was calculated retrospectively, and
patients were not managed based on this risk score. In addition, we did not evaluate gender-

collected so could not be used to calculate the HS.

TE

Conclusions

D

specific cut-offs which have been advocated.39 Hyperlipidemia and family history were not

Using the recommended 99th percentile cut-point for hs-cTnT, the combination of a HS with
non-elevated hs-cTnT values identifies a low-risk cohort who can be considered for discharge

EP

from the ED without further testing. The prognostic utility of this strategy is greatly lessened as

A

C

C

higher hs-cTnT cut-points are use.
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Table 1: Baseline characteristics
HEART Score ≥ 4 HEART Score ≤ 3

All Patients

Patients

Patients

Comparison

(N=612)

(N=623)

P-value

61.0 (50.0-74.0)

71.0 (61.0-78.0)

53.0 (45.0-62.0)

<0.001*

771 (62.4%)

397 (64.9%)

374 (60.0%)

0.079

White

1043 (84.5%)

548 (89.5%)

495 (79.5%)

<0.001*

Black

133 (10.8%)

37 (6.0%)

96 (15.4%)

Other

59 (4.8%)

27 (4.4%)

32 (5.1%)

Age, years
Male gender

D

(N=1235)

TE

Race

EP

Comorbidities

777 (62.9%)

496 (81.0%)

281 (45.1%)

<0.001*

263 (21.3%)

188 (30.7%)

75 (12.0%)

<0.001*

Hypercholesterolemia

480 (38.9%)

314 (51.3%)

166 (26.6%)

<0.001*

Current smoker

277 (22.4%)

97 (15.8%)

180 (28.9%)

<0.001*

Smoking history

731 (59.2%)

377 (61.6%)

354 (56.8%)

0.088

History of coronary

375 (30.4%)

323 (52.8%)

52 (8.3%)

<0.001*

History of PCI

275 (22.3%)

231 (37.7%)

44 (7.1%)

<0.001*

History of CABG

100 (8.1%)

92 (15.0%)

8 (1.3%)

<0.001*

History of AMI

305 (24.7%)

255 (41.7%)

50 (8.0%)

<0.001*

History of stable angina

144 (11.7%)

129 (21.1%)

15 (2.4%)

<0.001*

Hypertension

C

C

Diabetes

A

revascularization

pectoris
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158 (12.8%)

126 (20.6%)

32 (5.1%)

<0.001*

Cerebrovascular disease

127 (10.3%)

86 (14.1%)

41 (6.6%)

<0.001*

History of congestive heart

107 (8.7%)

91 (14.9%)

16 (2.6%)

<0.001*

2.8 (1.5-5.3)

2.9 (1.7-5.5)

History of unstable angina
pectoris

failure

Hours from onset to

Hours from onset to first

3.6 (2.3-6.2)

3.3 (2.0-5.9)

0.072

0.8 (0.7-1.0)

0.9 (0.7-1.1)

0.8 (0.7-0.9)

<0.001*
0.001*

EP

Systolic blood pressure (mm
Hg)

0.037*

3.4 (2.2-6.0)

blood draw
Creatinine (mg/dL)

2.6 (1.4-5.2)

TE

presentation

D

Presenting data and vital signs

141.0 (127.0-

144.0 (128.0-

140.0 (126.0-

157.0)

160.0)

153.0)
83.0 (74.0-93.0)

<0.001*

75.0 (64.0-88.0)

77.5 (67.0-88.0)

0.062

87 (7.0%)

68 (11.1%)

19 (3.0%)

<0.001*

Sinus rhythm

1130 (91.5%)

528 (86.3%)

602 (96.6%)

<0.001*

Other rhythm

18 (1.5%)

16 (2.6%)

2 (0.3%)

<0.001*

Left ventricular hypertrophy

65 (5.3%)

46 (7.5%)

19 (3.0%)

<0.001*

LBBB

36 (2.9%)

29 (4.7%)

7 (1.1%)

<0.001*

RBBB

55 (4.5%)

49 (8.0%)

6 (1.0%)

<0.001*

(mm Hg)
Heart rate

81.0 (72.0-90.0) 80.0 (70.0- 90.0)

C

Diastolic blood pressure

76.0 (66.0-88.0)

C

ECG findings and HEART score

A

Atrial fibrillation
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23 (1.9%)

23 (3.8%)

0 (0.0%)

<0.001*

Pathologic Q-waves

119 (9.6%)

87 (14.2%)

32 (5.1%)

<0.001*

ST-segment elevation

60 (4.9%)

53 (8.7%)

7 (1.1%)

<0.001*

ST-segment depression

164 (13.3%)

154 (25.2%)

10 (1.6%)

<0.001*

T wave-inversion

183 (14.8%)

133 (21.7%)

50 (8.0%)

<0.001*

Normal ECG

893 (72.3%)

312 (51.0%)

581 (93.3%)

<0.001*

Aspirin

633 (51.3%)

409 (66.8%)

224 (36.0%)

<0.001*

Anticoagulants

187 (15.1%)

131 (21.4%)

56 (9.0%)

<0.001*

Diuretics

304 (24.6%)

222 (36.3%)

82 (13.2%)

<0.001*

ACE inhibitor

369 (29.9%)

257 (42.0%)

112 (18.0%)

<0.001*

D

Paced ventricular complex

EP

TE

Medication History

Angiotensin receptor blocker

198 (16.0%)

131 (21.4%)

67 (10.8%)

<0.001*

Beta blocker

471 (38.1%)

338 (55.2%)

133 (21.3%)

<0.001*

236 (19.1%)

165 (27.0%)

71 (11.4%)

<0.001*

376 (30.4%)

263 (43.0%)

113 (18.1%)

<0.001*

Platelet inhibitor

170 (13.8%)

125 (20.4%)

45 (7.2%)

<0.001*

Anti-arrhythmic

64 (5.2%)

52 (8.5%)

12 (1.9%)

<0.001*

535 (43.3%)

377 (61.6%)

158 (25.4%)

<0.001*

C

Nitrates

C

Calcium antagonist

A

Other

ACE, angiotensin-converting enzyme; AMI, acute myocardial infarction; CABG, coronary artery bypass
graft; ECG, electrocardiogram; LBBB, left bundle branch block; PCI, percutaneous coronary
intervention; RBBB right bundle branch block.
Categorical data is given as frequency (percent of column) and numerical data is given as median
(interquartile range).
*

Statistically significant, P < 0.05
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Table 2: AMI/Death for modified HEART score ≤ 3 and ≥ 4 using different hs-cTnT cutpoints (19 ng/L) over various time intervals
hs-cTnT (ng/L) < various cut-

Death/AMI n (%) within 30 days Comparison
HS ≤ 3

P-value

0 hour

38 (9.9%)

13 (2.4%)

<0.001

0-2 hours

15 (4.6%)

3 (0.6%)

<0.001

0 – (4-14) hours

9 (3.0%)

3 (0.7%)

0.034

2X (38)

0 hour

79 (15.6%)

23 (4.1%)

<0.001

0-2 hours

49 (11.0%)

13 (2.5%)

<0.001

0 – (4-14) hours

34 (8.3%)

10 (2.2%)

<0.001

0 hour

96 (17.8%)

32 (5.5%)

<0.001

0-2 hours

66 (13.8%)

18 (3.4%)

<0.001

0 – (4-14) hours

57 (12.9%)

14 (3.1%)

<0.001

100 (18.3%)

41 (7.0%)

<0.001

EP

3X (57)

TE

99th% (19)

0 hour

C

4X (76)

0-2 hours

76 (15.4%)

24 (4.5%)

<0.001

0 – (4-14) hours

69 (14.9%)

16 (3.5%)

<0.001

0 hour

109 (19.5%)

46 (7.7%)

<0.001

0-2 hours

84 (16.7%)

27 (5.1%)

<0.001

0 – (4-14) hours

74 (15.8%)

19 (4.1%)

<0.001

0 hour

116 (20.5%)

46 (7.7%)

<0.001

0-2 hours

93 (18.2%)

31 (5.8%)

<0.001

0 – (4-14) hours

79 (16.7%)

22 (4.7%)

<0.001

120 (21.1%)

46 (7.7%)

<0.001

C
A

5X (95)

6X (114)

7X (133)

D

HS ≥ 4

points over different time intervals

0 hour
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32 (5.9%)

<0.001

0 – (4-14) hours

81 (17.0%)

24 (5.1%)

<0.001

0 hour

122 (21.3%)

47 (7.9%)

<0.001

0-2 hours

100 (19.3%)

33 (6.1%)

<0.001

0 – (4-14) hours

85 (17.7%)

24 (5.1%)

<0.001

0 hour

126 (21.9%)

48 (8.0%)

<0.001

0-2 hours

103 (19.7%)

35 (6.5%)

<0.001

0 – (4-14) hours

91 (18.7%)

27 (5.7%)

<0.001

0 hour

130 (22.4%)

49 (8.2%)

<0.001

0-2 hours

107 (20.3%)

37 (6.8%)

<0.001

0 – (4-14) hours

93 (19.0%)

27 (5.7%)

<0.001

10X (190)

EP

9X (171)

D

96 (18.6%)

TE

8X (152)

0-2 hours

99th%, 99th percentile; AMI, acute myocardial infarction; HS, HEART score; hs-cTnT, high-sensitivity
cardiac troponin T.

A

C

C

Statistically significant, P < 0.05
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Table 3: AMI/Death using different hs-cTnT cut-points over various time intervals
hs-cTnT (ng/L) < various cut-points Death/AMI n (%) within

2X (38)

0 hour

51 (5.5%)

0-2 hours

18 (2.2%)

0 – (4-14) hours

12 (1.6%)

0 hour
0-2 hours
0 – (4-14) hours

3X (57)

0 hour

0 – (4-14) hours

44 (5.1%)

128 (11.4%)
84 (8.4%)
71 (7.9%)

0 hour

141 (12.4%)

0-2 hours

100 (9.8%)

C

4X (76)

0 – (4-14) hours
0 hour

85 (9.2%)
155 (13.4%)
111 (10.7%)

6X (114)

0 hour

162 (14.0%)

0-2 hours

124 (11.8%)

0 – (4-14) hours

101 (10.8%)

A

C

5X (95)

62 (6.5%)

EP

0-2 hours

102 (9.5%)

TE

99th% (19)

30 days

7X (133)

D

over different time intervals

-2 hours

0 – (4-14) hours

93 (10.0%)

0 hour

166 (14.2%)

0-2 hours

128 (12.2%)
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9X (171)

10X (190)

0 hour

169 (14.5%)

0-2 hours

133 (12.6%)

0 – (4-14) hours

109 (11.5%)

0 hour

174 (14.8%)

0-2 hours

138 (13.0%)

0 – (4-14) hours

118 (12.3%)

0 hour
0-2 hours
0 – (4-14) hours

179 (15.2%)

TE

8X (152)

105 (11.1%)

D

0 – (4-14) hours

144 (13.5%)
120 (12.5%)

A

C

C

EP

99th%, 99th percentile; AMI, acute myocardial infarction; hs-cTnT, high-sensitivity cardiac troponin T.
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